Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT ID: NCT06087458
Last Updated: 2025-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2023-06-21
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
NCT05380492
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
NCT01941082
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
NCT01024998
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
NCT00090532
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VOY-101
Single intravitreal injection of VOY-101
VOY-101
VOY-101
Controll
Fellow Eye
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VOY-101
VOY-101
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are willing and able to understand and provide written informed consent.
* Are willing and able to return for scheduled treatment and follow-up examinations.
* Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
* Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
* Absence of signs of non-exudative MNV.
* Meet certain genotype criteria for risk of AMD.
Exclusion Criteria
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Perceive Biotherapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Fung, MD
Role: STUDY_DIRECTOR
Perceive Biotherapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Center of Texas
Southlake, Texas, United States
Retina Macula Institute of AZ
Scottsdale, Arizona, United States
The Retina Partners
Encino, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
Retina Consultants San Diego
San Diego, California, United States
Star Retina
Burleson, Texas, United States
University of Utah John A. Moran Eye Center
Salt Lake City, Utah, United States
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Cerulea Clinical Trials
East Melbourne, Victoria, Australia
Rambam Medical Center
Haifa, , Israel
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBI-AMD-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.